Our Company

viIMMUNE is an emerging biopharmaceutical company dedicated to the discovery and commercialization of innovative antiviral drugs. As a clinical stage company, viIMMUNE exploits small molecules as inhibitors of different enzymes in pathogenic viruses life cycle. Our mission at viIMMUNE is to help alleviate human suffering by discovering long-acting antiviral therapeutics through innovative approaches.

​

• viIMMUNE’s mission is to combat the life-threatening viral diseases

• The focus is on the clinical development of novel long-acting multifunctional anti-HIV and anti-SARS-CoV-2 agents

• The company has anti-HIV agents in pipeline exhibiting

  • longer duration of action by the sustained intracellular release of active substrates at adequate concentrations (in vivo animal data)

  • enhanced efficacy against resistant strains

  • higher uptake into infected cells

  • targeting hidden virus in the lymphatic system

​

viIMMUNE technology is based on cutting-edge science driven by the goal of developing therapeutics that last longer and give the patient more protection against viral diseases. Our proprietary library of small molecule candidates is stringently analyzed by our R&D team to select and develop agents optimally suited for this therapeutic approach.